The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Treatment-associated atrial fibrillation: ibrutinib-specific or class-specific?
Anthony Mato, MD, MSCE from the University of Pennsylvania, Philadelphia, PA presents the latest data from a cross-center study, investigating the incidence of ibrutinib-associated atrial fibrillation in chronic lymphocytic leukemia (CLL) patients. Up to 11% of patients receiving ibrutinib treatment will develop atrial fibrillation in the long term. By identifying those patients who are at a higher risk of developing this secondary condition, physicians can monitor patients and provide intervention when necessary. Dr Mato details the methods and results from this investigation. In addition, he goes on to discuss the incidence of atrial fibrillation following treatment with other classes of drugs in CLL. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY.
